Answers are grounded in this paper and cite their sources.
Snakebite envenomation remains a critical neglected tropical disease, affecting approximately 5.4 million people annually and causing 81,000–138,000 deaths worldwide. Traditional antivenoms, predominantly animal-derived immunoglobulins, face significant limitations including high production costs, cold-chain dependency, hypersensitivity reactions and limited efficacy against venom-induced tissue necrosis, particularly low molecular mass toxins responsible for local tissue damage. This review synthesizes current knowledge on natural bioactive compounds—including alkaloids, flavonoids, tannins, terpenes, saponins, coumestans, sulphated polysaccharides, phenolic acids (gallic acid, ellagic acid, caffeic acid, ferulic acid, rosmarinic acid and chlorogenic acid) and endogenous human proteins—as alternative or adjunctive therapies for snakebite management. We examine their sources, mechanisms of action, structure-activity relationships and therapeutic potential against key venom toxins including phospholipase A₂ (PLA₂), snake venom metalloproteinases (SVMPs), and serine proteases. Plant-derived secondary metabolites demonstrate broad-spectrum inhibition of venom enzymes through active-site binding (flavonoids, coumestans, terpenes), metal chelation (tannins, gallic acid, quinones), protein precipitation (tannins, saponins, quinones) and antioxidant and anti-inflammatory activities. Endogenous human proteins—serum albumin, tissue inhibitors of metalloproteinases (TIMPs), C-reactive protein (CRP) and antithrombin III—offer complementary neutralisation with reduced immunogenicity, though circulating concentrations of TIMPs (50–100 ng/mL) and CRP (< 10 mg/L) are substantially below therapeutic requirements, necessitating exogenous supplementation. Notably, plant-derived compounds also inhibit catalytically inactive Lys49 PLA₂ homologues—a capability that conventional antivenoms lack—representing a significant advantage for managing venom-induced myotoxicity and edema. Synergistic combinations of endogenous proteins with phytochemicals, operating through multi-target binding, allosteric modulation, sequential neutralization, complementary pharmacokinetics and reduced immunogenicity, present a promising framework for next-generation, multi-target antivenom therapies. Recent advances in computational biology, including molecular docking, molecular dynamics simulations and AI-driven drug discovery, have accelerated the identification and optimization of plant-derived venom inhibitors as demonstrated by the identification of labdane lactone (83% inhibition at 22.7 µM) and anisic acid (100% neutralization) through virtual screening. However, despite extensive preclinical validation, no bioactive compound has yet progressed to clinical trials for snakebite envenomation—a critical translational gap that this review systematically addresses through a proposed Phase I–III clinical translation framework. This review critically evaluates the current evidence base, identifies lead candidates, compares natural products with classical inhibitors (EDTA, PMSF, benzamidine ) and proposes a structured clinical translation pathway, including trial design, regulatory considerations, nanotechnology-based delivery systems, recombinant antivenoms, monoclonal antibodies and integration with WHO snakebite strategies. The review is organized into nine interconnected sections covering bioactive compound classes, sources, mechanisms, structure-activity relationships, integration with existing antivenom frameworks, ethnobotanical perspectives, challenges including chemical stability and formulation and future directions. By bridging traditional knowledge with modern pharmacology, this review provides a forward-looking framework for developing accessible, cost-effective and safer alternatives for snakebite management, contributing to Sustainable Development Goal 3 (Good Health and Well-being) and addressing a pressing global health inequity.
No takes yet. Share an insight, caveat, or question.
Fubara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: